Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) with a Buy rating and $127 price target following news from partner Sage ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Goldman Sachs Starts Sage Therapeutics (SAGE) at BuyMay 15, 2015 7:02 AM Sage Therapeutics (SAGE) PT Raised to $70 at Leerink Partners as New Data Corroborates Prior Promising ResultsMay 14, 2015 11:03 AM